We have constructed a prostate-specific lentiviral vector based on the promoter of the prostate-specific antigen (PSA). The PSA promoter-based lentiviral vector has been used to deliver the diphtheria toxin A (DTA) gene into prostate cancer cells, and has shown promising tissue-specific eradication of prostate cancer cells in cell culture. To evaluate the efficacy of eradicating human prostate cancer cells in vivo, we used human LNCaP prostate xenografts in nude mice as an animal model and found that with a single injection of the DTA lentiviral vector into LNCaP prostate tumors, approximately 75% of the tumors (from three experiments; conducted 9/11, 11/15 and 3/4) in the animals were completely eradicated. The DTA vector has also shown the ability to cause tumor regression in recurrent prostate tumors. Intravenous injection of the DTA lentiviral vector into nude mice elicited no pathogenic effects, suggesting that this prostate tissue-specific vector is safe for eradicating prostate cancer cells in vivo.
P rostate cancer is the leading malignancy in American men. There is currently no effective cure for patients in advanced stages of the disease, and development of new therapeutic modes is needed. We propose to use gene therapy as an approach to treat these patients. We constructed a prostate tissue-specific promoter by combining the prostate-specific antigen (PSA) promoter (the promoter of the prostate-specific antigen gene) and the upstream regulatory sequence of the PSA gene (PSAR) isolated from prostate tumor tissue excised from a patient in an advanced disease stage. 1, 2 Using reporter genes such as luciferase (Lux) or the enhanced green fluorescent protein (EGFP), this constructed promoter, PSAR-PCPSA, demonstrated greater than 1000-fold tissue specificity in plasmid vectors. 2 This highly tissue-specific property shows great promise for transcriptional targeting of prostate cancer cells in vivo. This promoter drives therapeutic genes in a gene delivery vector and confines expression of these genes only to prostate cells, thereby providing a safe approach to treating prostate cancer in patients.
As a plasmid vector may not provide efficient gene delivery, it is unlikely that use of this type of vector would be satisfactory for treating prostate cancer in vivo. To increase gene delivery efficacy, our laboratory and others have tested adenoviral vectors, [3] [4] [5] which greatly increase gene delivery efficacy. However, tissue specificity is decreased to approximately 20-fold or even lower with adenoviral vectors thus far tested, [3] [4] [5] [6] diminishing the feasibility of using adenoviral vectors for target-specific gene therapy.
In addition to progress made in developing ''gutless'' adenoviral vectors that may overcome the issue of decreased tissue specificity of the prostate-specific promoter in classic adenoviral vectors, 6 we have tested a lentiviral vector. Lentiviral vectors offer efficacious gene delivery. [7] [8] [9] [10] [11] Lentiviral vectors are enclosed by an envelope derived from the host (human) cell membrane. Although there are some considerations concerning the safety of lentiviral vectors, since some sequences are derived from HIV (comprised of B25% HIV sequences), this type of gene therapy vector has been proven to be very safe. There is no evidence to suggest that lentiviral vectors are capable of self-replication after infection. The new generation of lentiviral vectors have a self-inactivating (SIN) feature, 12, 13 which prevents the vectors from replicating even in the presence of all required viral assembly proteins.
Our in vitro and in vivo experiments have demonstrated that the PSAR-PCPSA-based lentiviral vector is highly tissue-specific.
14 However, although the PSAR-PCPSA lentiviral vector expresses its gene specifically in target cells, additional factors, including an appropriate gene to inhibit or eradicate cancer cells, are required for efficient therapeutic effects.
Our cell culture experiments have demonstrated that the DTA gene is a suitable candidate for eradicating prostate cancer cells. 14, 15 However, because gene delivery efficiency is significantly lower in vivo, eradication of cancer cells in vivo is more difficult than eradication of cancer cells in cell culture. Here, we report usage of LNCaP prostate cancer cells xenografted into nude mice as an animal model in which to test the PSAR-PCPSA-DTA lentiviral vector. Injection of the DTA lentiviral vector demonstrated significant tumor regression, suggesting that the combination of the PSAR-PCPSA tissuespecific promoter, the DTA gene, and the lentiviral vector has unprecedented potential for eradicating prostate cancer in vivo.
Materials and methods

Cell lines and maintenance
The PSA-producing cell line, LNCaP, was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). The renal cell carcinoma control cell line, R11, has been previously described. 14, 15 Both the cell lines were maintained in RPMI medium with 10% fetal bovine serum from Gibco-BRL.
Growing LNCaP prostate and control tumors in nude mice
LNCaP cell cultures with approximately 50% confluence in T162 flasks were harvested by trypsin-EDTA digestion for 3 minutes at 371C, and washed once with phosphatebuffered saline (PBS). The cells were recovered by centrifugation at 1000 rpm for 3 minutes with an Eppendorf desktop centrifuge. The cells were resuspended in Matrigel (Fisher Scientific, Pittsburgh, PA) at a cell density of 3.5 Â 10 7 /ml at 41C before being injected subcutaneously into each nude mouse (Charles River Laboratory) at 5 Â 10 6 cells/mouse. Visible LNCaP tumors developed approximately 7-14 days postinjection. Either the diphtheria toxin A (DTA) or the control viral vector was injected into the tumors when tumors grew to an average diameter of approximately 3-5 mm. Control R11 cells in serum-free RPMI medium were subcutaneously injected into nude mice at a dose of 1 Â 10 6 cells/ mouse. Visible R11 tumors developed approximately 7 days postinjection. As R11 tumors grow faster than LNCaP tumors in nude mice, we found that 1 Â 10 6 cells is sufficient for tumor development in controls comparable to experimental nude mice.
Lentiviral vectors
Construction, preparation and concentration of the lentiviral DTA and EGFP vectors have been previously described. [7] [8] [9] [10] [11] [12] [13] [14] The crude viral suspension harvested from transfected 293T cell cultures was quantified by measuring levels of the Gag protein, p24, in viral stocks. Infectious titers of the viral vector containing the EGFP reporter were also determined, using limited dilution to infect LNCaP cells. A viral aliquot containing 1 pg of p24 gag protein equals 1-10 infectious units. We concentrated the crude viral stocks by ultracentrifugation, 9, 14 after which the pellet containing the viral vector was concentrated to 1/100th of the original volume. Final concentrations were approximately 2-5 mg p24/ml. The concentrated viral stocks were saved in 1-ml aliquots per tube in a À801C freezer.
Injection of lentiviral vectors into tumors and tail veins of mice
The DTA or the control vector containing the EGFP gene (0.2 ml of either) was intratumorally injected into LNCaP tumors in mice using #26 gauge disposable needles from Becton, Dickinson and Company (Franklin Lakes, NJ). The first injection was performed when the tumors reached approximately 3-5 mm diameter. Repeated injections were administered for tumors that did not show significant response to previous injections. As repetitive freeze/thaw cycles may decrease viral infectious titers at unpredictable rates, unused virus was discarded. Injection of mouse tail vein was performed by using either the lentiviral DTA vector of a lentiviral vector carrying the CMV-EGFP gene expression cassette. Mouse tail was cleaned using ethanol wiping followed by injection of viral vectors using #28 gauge needles.
Results
Eradication of LNCaP prostate cancer cells in nude mice by the lentiviral DTA vector
We found that with the addition of Matrigel, the injected ). We injected either the DTA or the EGFP control vector into these tumors.
In control studies, we treated fewer animals with lentiviral vector carrying the EGFP gene because our previous studies using cell cultures clearly demonstrated that the EGFP lentiviral vector has minimal effect in eradicating LNCaP prostate cancer cells. The use of six mice should be sufficient to conclude whether lentiviral vector carrying the nontoxic gene can eradicate prostate cancer in vivo. If unexpected results were demonstrated, we would have used more mice to repeat the experiments.
Significant tumor regression was demonstrated 4-7 days postinjection of the DTA vector, whereas no tumor regression was observed in the tumors injected with the EGFP lentiviral vector (Fig 1) , suggesting that the DTA lentiviral vector was more efficient in eradicating tumors smaller than 10 mm
). Injection of the DTA vector into these smaller tumors resulted in 100% tumor regression (Fig 1a) , as well efficient eradication of larger LNCaP tumors (Fig 1b) . In the first round of experiments, we found that five the seven larger tumors showed complete response to the DTA vector (Fig 1b) . For most tumors, steady regression was demonstrated for 2-3 weeks. However, DTA-induced tumor regression did not last long in some of the tumors (Fig 1b) . Some tumors resumed growth 1 or 2 weeks postinjection, suggesting that the growth potential of the surviving cancer cells in these animals had not actually changed.
We repeated these experiments, using different viral stocks. In repeat testing, 10 of the 15 treated tumors in nude mice completely disappeared (Fig 2a) , and two others had almost complete response, with only very small nodules remaining, which might have been scars, since they did not grow (Fig 2b) . Only three of the 15 tumors (one shown in Fig 2a and two in Fig 2b) showed significant recurrent growth. The response ratio is therefore similar to that seen in the first round of experiments.
To determine whether the surviving LNCaP cells are resistant to the DTA vector, we injected the DTA vector into the two recurrent tumors shown in Figure 1b , and the three tumors shown in Figure 2a and b, and found that the DTA vector efficiently inhibited the growth of four of these five tumors (two shown in Fig 1b, one in Fig 2a and  one in Fig 2b) , suggesting that the DTA vector can also eradicate cancer cells in recurrent tumors. Additional testing also confirmed that repetitive injections of the DTA lentiviral vector inhibited the growth of recurrent tumors (Fig 2c) . However, we noted that one of the surviving tumors showed resistance to the DTA vector (Fig 2b) , and this mechanism of resistance is currently being investigated.
We previously reported that our prostate tissue-specific lentiviral vector has very low levels of expression in all the tested control cell lines, including the non-PSA-producing prostate cell line, DU145; the renal cell carcinoma cell line, R11; the breast cancer cell line, MCF-7; and the embryonic cell line, 293. To investigate tissue-specific expression of the DTA vector in vivo, we grew R11 renal cells in nude mice. When the R11 tumors reached 4-5 mm in diameter, we injected the same dose of lentiviral DTA vector into these tumors. As expected, no tumor regression occurred in any of the tested animals (Fig 2d) .
Evaluation of pathogenic effects in animals injected with the DTA vector
To assess potential toxicity when using lentiviral vectors to deliver therapeutic genes, we first used a lentiviral vector that carries the CMV-luciferase gene expression cassette to characterize the profile of lentiviral vector distribution in vivo. We injected via tail vein the CMVluciferase viral vector with a p24 count of 100 ng (containing approximately 10 5 -10 6 infective virions) into mice carrying LNCaP tumors. Significant expression was detected in the spleen, lung and kidney (Fig. 3) , suggesting " that the lentiviral vector is able to infect cells in different organs. We subsequently evaluated the safety of our DTA vector in nude mice to determine whether the DTA gene driven by the PSA promoter was able to confine expression of DTA to prostate cells. We intravenously injected three-fold higher doses (three injections of 0.2 ml of DTA vector per mouse) of our tissue-specific lentiviral vector into nude mice. No pathogenic effects were observed in the five treated mice for 90 days, suggesting that the PSAR-PCPSA promoter can efficiently control expression of the DTA gene in vivo by limiting toxic gene expression to prostate cells, thereby providing a safe means of treating prostate cancer. As the expression of the gene carried by the infected lentiviral vector decreases to less than 3% at 90 days postinfection in various tissues, 10, 11 it is unlikely additional pathogenic effects could be developed after 90 days postinjection. We also collected the organs that are more liable to lentiviral infection, including the spleen, kidney, lung and liver from mice injected with the DTA vector and from mice injected with medium only. Tissue sections from DTA vector injected mice were compared with tissue sections from mice injected with RPMI medium, and no pathogenic effect in the organs from mice treated with the DTA vector has been demonstrated as compared to the untreated mice (Fig 4) .
Discussion
Transcriptionally targeting cancer cells with tissue-specific promoters has shown great promise. [16] [17] [18] [19] [20] Therapeutic genes that are driven by a prostate-specific promoter have demonstrated selective expression in prostate but not other cells in vitro and in vivo. 1, 2, 14, [21] [22] [23] [24] [25] In addition to a prostate-specific promoter, efficient and safe delivery of the gene expression cassette and a potent therapeutic gene are necessary for targeting and treating prostate cancer cells. We previously demonstrated that efficient and tissue-specific cancer cell eradication was achievable in cell culture, using the combination of the PSA promoter, the DTA gene, and the lentiviral vector.
14, 15 The results reported here indicate that significant cancer cell eradication can also be achieved in vivo.
The concentration of our DTA vector stocks, as determined by p24 titers, was 2-5 mg/ml p24 counts. Since 6 cells. Therefore, the number of vector particles should be adequate to infect a significant percentage of prostate cancer cells in vivo, we would expect that more than 5% of the cancer cells would express the DTA gene. In combination with the so-called ''bystander'' effect, 14, 15 all cancer cells could be eradicated. As smaller tumors contain fewer cells, the same amount of virus should result in better rates of infection, and greater tumor regression would be expected. In our studies, we found that the DTA vector was more efficient in smaller tumors, supporting this hypothesis.
We note that the injection of the DTA vectors failed in eradication of approximately 20% of the tumors. Some tumors responded to the DTA vector in the beginning, but resumed growth later (Fig 1b and 2b) . At least one tumor developed resistance to the DTA vector (Fig 2b) . We speculate that the PSA promoter may not be active in some LNCaP cells. Some of these cells could be eradicated as a result of the by-stander effect, while some may survive. We used the PSA promoter-based lentiviral vector to deliver the EGFP gene into LNCaP cells in culture and found that approximately 80% of the cells showed EGFP positive, 15 which is lower than using the vector carrying the CMV-EGFP gene expression cassette (95%). It is likely that the PSA promoter is not active in approximately 15% of LNCaP population.
We expect that a fraction of the lentiviral vector may not be absorbed by prostate tumor cells, but could leak to capillary vessels. The leaked portion of viral vector may infect endothelial cells in blood vessels and other organs or tissues, including the liver, kidney and lung. In these tissues or organs, the DTA gene, driven by the tissuespecific promoter, would not be expressed. Thus, a tissuespecific vector may be safer for intratumoral injection.
Intravenous injection of the DTA vector into mice showed no pathogenic effects, suggesting that when this gene is controlled by the PSAR-PCPSA promoter in a lentiviral vector, the DTA gene is safe in this setting, despite its inherent toxicity. We are now experimenting with higher doses of the DTA vector injected into mice to determine a maximal dose. It would be possible to use systemic injection to treat metastatic prostate cancer in vivo if high doses of the DTA vector do not elicit significant pathogenic effects. As we have not generated nontissue-specific lentiviral DTA vector, direct comparison between the PSA promoter-based lentiviral DTA vector and the CMV promoter-based DTA lentiviral vector is not performed. A possible approach to generating nontissue-specific DTA vector is to use DTA-resistant cell lines. 26 Another feature of lentiviral vectors is the integration of viral genome. This feature confers durable gene expression upon the carried genes. However, modifications of the integrated viral genome will eventually turn off the expression of the carried genes. Generally, highest expression is demonstrated within the first week postinfection and then expression of the gene carried by the infected lentiviral vector decreases. 10, 11 Such effects are also demonstrated in our tests. In most cases, tumor regressions were demonstrated within one week.
We used VSV-G protein to modify the envelope of the lentiviral DTA vector. Similar strategy has been used by many laboratories. [7] [8] [9] [10] [11] [12] [13] The addition of this protein greatly increases gene transduction. However, since VSV-G is not tissue-specific, lentiviral vectors with this protein on their envelope infect many types of cells. A potential problem is the infection of lymphocytes in circulation. Such infection may affect the function of the immune system in treated individuals. The expression of the transgene in spleen suggests that many lymphocytes can be infected by systemic injection of VSV-G modified lentiviral vectors. Similar results have also been reported by others. 27 A Spleen Liver Kidney Lung DTA Control 0.25 mm Figure 4 Tissue sections of DTA vector-treated and untreated mice. Tail vein injection delivered approximately 0.2 ml of the DTA lentiviral vector with a 3.5 mg p24/ml p24 count. Subsequent injections were administered weekly. After three injections, the treated mice were killed for pathogenic assays. Mice injected with RPMI medium were used as controls. At 2 weeks postinjection of the DTA vector or medium, mice were killed and organs were saved and fixed using 4% formaldehyde in PBS and stained using Mayer's hematoxylin-eosin (HE).
fraction of lymphocytes infected by lentiviral vectors carry-ing reporter genes may not significantly affect the function of immune system. We expect that DTA expression of our tissue-specific lentiviral vector in lymphocytes should be very low, therefore, it is unlikely that systemic injection of the DTA vector can seriously damage immune system. More studies to quantify the expression of the PSA-promoter based lentiviral vector in various cells of the immune system are under investigation. One of the major disadvantages of using lentiviral vectors is the low titer of viral stocks. Currently available procedures do not render highly purified and concentrated lentiviral vectors. 28, 29 In our studies, we used ultracentrifugation to prepare the DTA lentiviral vector, and obtained vector stocks with concentrations of approximately 2-5 mg/ml p24 counts. Previous reports indicated that 1 pg of p24 Gag protein is equivalent to 1-10 infectious viral particles; 14 thus, a vector stock with a 5 mg/ml p24 count contains approximately 5 Â 10 7 /ml viral particles or fewer, significantly lower than adenoviral vectors prepared in laboratories. [30] [31] [32] While the lentiviral vector is derived from HIV-1, use of the three-plasmid cotransfection method does not generate wild-type HIV-1, but it is possible that an HIV-like virus may be generated, which uses the VSV-G protein as its envelope and contains all the genes required for viral replication. However, to date, there has been no report of replicating lentiviral vectors being generated by the three-plasmid cotransfection procedure. As functional HIV env gene sequence is not present in any one of the three plasmids used in generating the DTA lentiviral vector, it is unlikely that wild-type HIV can be generated by any recombination between the plasmids. However, it may be safer to delete more sequence spans from the env gene of the packaging plasmid. 9 More extensive experimentation is necessary to completely nullify the possible risks of lentiviral vectors.
